Celebrating our 10th anniversary – Unlock our special offer today

Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Europe European Parliament adopts proposal about right to repair of goods ...
  • Germany BGH sets limit for 'small amount' of cannabis ...
  • United States CPC’s new legislative agenda prioritises cannabis legalisation ...
  • Lithuania Proposed changes to fibre hemp regulation to go to Seimas this week ...
  • Turkey Ministry urged to legalise hemp cultivation in Karaman province ...
  • Missouri - United States Attorney general issues CIDs over illegal marketing practices ...
  • Minnesota - United States Cannabis and hemp bill passes House and heads to Senate ...
  • Germany Government wants to tighten rules around new cannabis law ...
  • Israel Procedure to acquire medical cannabis export licence updated ...
  • France Bill introduced to try legalising recreational cannabis based on German model ...
  • North Dakota - United States Over 15,000 signatures needed to get adult-use cannabis legalisation on ballot ...
  • Kentucky - United States Bill signed into law makes changes to medical cannabis regulation ...
View all
News analysis

German pharma firm buys €80m C3 to boost its European cannabis presence

Written by || 26th January 2022 || News analysis | Companies | GeographiesCanada Europe Germany North America

This story examines the significance of German pharma group Dermapharm’s acquisition of the Germany based Cannabinoid Compound Company (C3) from Canadian owner Canopy Growth. We show how it’s an opportunity for Dermapharm to expand in the European medical cannabis market, but represents a considerable loss for Canopy after only three years’ ownership.

Read full article

Download the full news analysis

“German pharma firm buys €80m C3 to boost its European cannabis presence”








    I'm already a subscriber

    Login

    Author default picture

    CannIntelligence

    This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

    Our Key Benefits

    The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

    CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

    • Stay informed of any legal and market change in the sector that impacts your organisation
    • Maximise resources by getting market and legal data analysis daily in one place
    • Make smart decisions by understanding how the regulatory and market landscape evolves
    • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

    Thanks for getting in touch with us

    Please leave your enquiry and we will get back to you within 24 hours


      Sign up to our newsletter

      Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis


        See more


        By signing up you agree to our Privacy Policy.